Table 1.
Demographic characteristics.
| AG | ACG | RG | RCG | |
|---|---|---|---|---|
| Participants | n = 120 | n = 32 | n = 105 | n = 39 |
| Gender, n (%) | ||||
| Female | 76 (63) | 22 (69) | 75 (71) | 31 (80) |
| Male | 44 (37) | 10 (31) | 30 (29) | 8 (20) |
| Mean age, y (±SD) | 23.3 (±7.1) † | 25.5 (±7.7) | 46.1 (±15) | 40.9 (±11.6) |
| Range of age, y | 43 | 41 | 61 | 40 |
| BMI, kg/m2 | 23.1 † | 22.9 | 24.8 | 23.4 |
| Body fat, % | 25.3 †† | 30.1 | 36 | 34.2 |
| Clinical acne assessment, n (%) | ||||
| Acne comedonica | 29 (24) | |||
| Acne papulopustulosa | 84 (70) | |||
| Acne conglobata | 7 (6) | |||
| Clinical rosacea assessment, n (%) | ||||
| Persistant erythema/telangiectasia | 65 (62) | |||
| Papules/pustules | 34 (32) | |||
| Phymata | 5 (5) | |||
| Ocular symptoms | 1 (1) | |||
| Mean disease persistence, y | 5.9 | 6.6 | ||
| Regular supplement intake, n (%) | 52 (43.3) * # | 19 (59.4) | 62 (59.6) | 26 (66.7) |
| Facial sebum, mean (µg/cm2) | 136.3 † | 89 | 136.7 † | 103.2 |
| DLQI, mean (±SD) | 6.5 † † (±5.0) | 1.6 (±3.4) | 5.4 † (±5.6) | 0.67 (±1.3) |
| EQ-5D-3L, mean (±SD) | 76.5 † (±18.2) | 89.7(±11.8) | 73.04 † (±19.5) | 89.15 (±8.4) |
(AG = acne group, ACG = acne control group, RG = rosacea group, RCG = rosacea control group, BMI = body mass index, DLQI = Dermatology Life Quality Index, EG-5D-3L = European Quality of Life 5 Dimension 3 Level, n = number, SD = standard deviation, y = year); * = p < 0.05 AG vs. ACG, RG vs. RCG; # = p < 0.05 AG vs. RG; † = p < 0.01 AG vs. ACG, RG vs. RCG; † = p < 0.01 AG vs. RG.